Tyler Rencher, DO
Internal Medicine · Saint George, UTNPI 1649614744
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $829 and has fallen 87.8% since, to $101 in 2025.
Across 161 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$403
- Johnson & Johnson$290
- Pfizer$252
- Amgen$183
- Novo Nordisk$177
- AstraZeneca$167
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,696100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $403 |
| Johnson & Johnson | 16 | $290 |
| Pfizer | 15 | $252 |
| Amgen(2 entities) | 9 | $183 |
| Novo Nordisk | 12 | $177 |
| AstraZeneca(2 entities) | 12 | $167 |
| Merck | 9 | $130 |
| Lilly USA, LLC | 8 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $118 |
| IBSA Pharma Inc. | 5 | $97 |
| Boehringer Ingelheim | 5 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $88 |
| Boston Scientific | 4 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| Lucid Diagnostics Inc. | 2 | $50 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Strongbridge US Inc. | 2 | $37 |
| Medtronic(2 entities) | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Bayer | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$2,697 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $43,765 |
| MounjaroTirzepatide | 21 | $26,789 |
| OzempicSemaglutide | 12 | $21,054 |
| JardianceEmpagliflozin | 14 | $14,716 |
| Gabapentin | 97 | $1,962 |
| Duloxetine Hcl | 35 | $1,800 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $1,494 |
| Atorvastatin Calcium | 119 | $1,454 |
| Levothyroxine Sodium | 127 | $1,365 |
| Liothyronine Sodium | 47 | $1,200 |
| Losartan Potassium | 78 | $1,137 |
| Omeprazole | 62 | $1,136 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,075 |
| Ondansetron OdtOndansetron | 27 | $872 |
| Fluoxetine Hcl | 34 | $830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $252 | $43,76541 claims |
| Lilly USA, LLCMounjaro | $122 | $26,78921 claims |
| Novo NordiskOzempic | $177 | $21,05412 claims |
| Boehringer IngelheimJardiance | $89 | $14,71614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Saint George
- Joseph WoolleySaint George$10K
- Richard BennettSaint George$5K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
- Barbara RizzardiSandy$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.